Skip to main content

Gibela Therapeutics, a spin-off from the Cooperative Research Center in Biosciences (CIC bioGUNE), is pioneering RNA-based therapeutics for the treatment of liver diseases.

The company, founded by Dr. Malu Martínez-Chantar, Dr. Naroa Goikoetxea, and Nicholas Benedict, has developed an innovative RNA-based therapy that focuses on modulating mitochondrial activity and endoplasmic reticulum stress—two key hub processes in liver disease pathogenesis.

Recent publications in top journals such as Journal of Hepatology, Nature Communications, and Hepatology have demonstrated the broad therapeutic potential of Gibela’s approach across various liver pathologies.

Gibela Therapeutics is actively advancing its pipeline to target both high-prevalence liver diseases and those with lower incidence, with a strong emphasis on personalized medicine.

By tailoring treatments to individual patient profiles, the company aims to redefine the therapeutic landscape for liver diseases, offering innovative and effective solutions.

We are excited to welcome Gibela Therapeutics to our portfolio!

Share this article

View all news

Sign up to receive our newsletter in your inbox.